Six-month data back Biotronik's absorbable metal stent:
This article was originally published in Clinica
Executive Summary
Six-month follow-up studies from the first human trials of an absorbable metal stent (AMS) developed by Biotronik, have shown the device to be safe and effective when used to treat blocked arteries below the knee. Only one of the 20 stent recipients needed an amputation during the follow-up period, the Berlin, Germany firm said, adding that this was an "excellent" outcome since all the patients were high-risk. Some 79% of each stented vessel remained patent, indicating that the arteries remained stabilised even after the stent had been absorbed, a process that takes between two and three months to complete.